Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Ann Allergy Asthma Immunol ; 113(1): 108-13, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24745701

ABSTRACT

BACKGROUND: Symptom scoring for the assessment of allergen immunotherapy is associated with a substantial placebo effect. OBJECTIVE: To assess the ability of exhaled breath temperature (EBT), a putative marker of airway inflammation, to evaluate objectively the efficacy of grass pollen sublingual immunotherapy in a proof-of-concept study. METHODS: This was a double-blinded, placebo-controlled clinical trial in 56 subjects (mean ± SD 30 ± 12 years old, 33 men) sensitized to grass pollen. The objective measurements were EBT, spirometry, and periostin and high-sensitivity C-reactive protein in blood. Overall discomfort scored on a visual analog scale was used as a proxy for subjective symptoms. Evaluations were performed before, during, and after the grass pollen season. RESULTS: Fifty-one subjects (25 and 26 in the active treatment and placebo groups, respectively) were assessed before and during the pollen season. The mean pre- vs in-season increase in EBT was significantly smaller (by 59.1%) in the active treatment than in the placebo group (P = .030). Of the other objective markers, only the blood periostin level increased significantly during the pollen season (P = .047), but without intergroup differences. Subjectively, the mean pre- vs in-season increase in the visual analog scale score was 32.3% smaller in the active treatment than in the placebo group, although this difference did not reach statistical significance (P = .116). CONCLUSION: These results suggest that the efficacy of grass pollen sublingual immunotherapy can be assessed by EBT, a putative quantitative measurement of airway inflammation, which is superior in its power to discriminate between active and placebo treatment than a subjective assessment of symptoms assessed on a visual analog scale. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01785394.


Subject(s)
Allergens/administration & dosage , Conjunctivitis, Allergic/therapy , Exhalation , Pollen/adverse effects , Rhinitis, Allergic, Seasonal/therapy , Sublingual Immunotherapy , Administration, Sublingual , Adolescent , Adult , Biomarkers/analysis , C-Reactive Protein/metabolism , Cell Adhesion Molecules/blood , Conjunctivitis, Allergic/complications , Conjunctivitis, Allergic/immunology , Conjunctivitis, Allergic/pathology , Double-Blind Method , Female , Humans , Male , Placebos , Poaceae/adverse effects , Rhinitis, Allergic, Seasonal/complications , Rhinitis, Allergic, Seasonal/immunology , Rhinitis, Allergic, Seasonal/pathology , Temperature
2.
Protein Pept Lett ; 15(4): 353-5, 2008.
Article in English | MEDLINE | ID: mdl-18473946

ABSTRACT

The sheep skins unhairing process with preliminary alkaline treatment of the wool leads to two unnatural dipeptide mimetics lysinoalanine (Lys(*) - Ala) and ornithinoalanine (Orn(*)- Ala) obtaining. They are result from the keratin hydrolysis process. The changes of wool keratin make it resistant to sulphide degradation. We synthesized and characterized these unnatural dipeptides under the experimental conditions. The structures and mechanism of Lys(*) - Ala and Orn(*)- Ala obtaining were elucidated. The using of newly synthesized products as markers for control of wool's keratin changes during skin unhairing process was demonstrated. The developments have also been the result of economic and environmental pressures to meet environmental regulations.


Subject(s)
Alanine/chemical synthesis , Dipeptides/chemical synthesis , Keratins/chemistry , Lysinoalanine/chemical synthesis , Ornithine/chemical synthesis , Wool/chemistry , Alanine/analysis , Alanine/chemistry , Animals , Dipeptides/analysis , Dipeptides/chemistry , Lysinoalanine/analysis , Lysinoalanine/chemistry , Ornithine/analysis , Ornithine/chemistry , Sheep , Skin
SELECTION OF CITATIONS
SEARCH DETAIL
...